We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+17.81%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$5.3B
AUM Growth
+$879M
(+20%)
Cap. Flow
+$397M
Cap. Flow
% of AUM
7.5%
Top 10 Holdings %
Top 10 Hldgs %
58.3%
Holding
63
New
4
Increased
10
Reduced
3
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$371M |
| 2 |
Legend Biotech
LEGN
|
+$250M |
| 3 |
Axsome Therapeutics
AXSM
|
+$73.8M |
| 4 |
NewAmsterdam Pharma
NAMS
|
+$66.3M |
| 5 |
4D Molecular Therapeutics
FDMT
|
+$56.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMGN
Immunogen Inc
IMGN
|
+$231M |
| 2 |
BLU
BELLUS Health Inc.
BLU
|
+$91M |
| 3 |
Celldex Therapeutics
CLDX
|
+$62.4M |
| 4 |
HLVX
HilleVax
HLVX
|
+$29.1M |
| 5 |
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
|
+$26.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma A/S
ASND
$16.5B
| $1B | 18.92% |
11,225,357
+4,268,178
| +61% | +$371M |
|
|
2
Legend Biotech
LEGN
$3.65B
| $432M | 8.16% |
6,264,707
+3,828,484
| +157% | +$250M |
|
3
Vaxcyte
PCVX
$7.65B
| $394M | 7.44% |
7,891,254
+600,000
| +8% | +$28.4M |
|
|
DICE
4
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $365M | 6.89% |
7,856,612
| – | – |
|
|
ETNB
5
DELISTED
89bio
ETNB
| $216M | 4.08% |
11,416,948
| – | – |
|
6
Biogen
BIIB
$30.9B
| $152M | 2.87% |
532,892
| – | – |
|
|
JBIO
7
Jade Biosciences
JBIO
$1.18B
| $142M | 2.68% |
236,114
| – | – |
|
|
VRNA
8
DELISTED
Verona Pharma
VRNA
| $134M | 2.52% |
6,317,990
| – | – |
|
|
CVAC
9
DELISTED
CureVac
CVAC
| $128M | 2.41% |
12,245,955
| – | – |
|
10
Tyra Biosciences
TYRA
$1.85B
| $123M | 2.33% |
7,236,454
| – | – |
|
|
11
NewAmsterdam Pharma
NAMS
$3.26B
| $107M | 2.02% |
9,000,000
+5,000,000
| +125% | +$66.3M |
|
12
Cytek Biosciences
CTKB
$566M
| $105M | 1.98% |
12,297,721
-1,083,333
| -8% | -$9.72M |
|
13
Janux Therapeutics
JANX
$912M
| $103M | 1.94% |
8,670,644
| – | – |
|
14
Geron
GERN
$898M
| $101M | 1.91% |
31,544,806
| – | – |
|
|
INBX
15
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $100M | 1.89% |
3,853,867
| – | – |
|
16
Rhythm Pharmaceuticals
RYTM
$7.31B
| $93.6M | 1.77% |
5,676,067
+160,000
| +3% | +$2.89M |
|
|
DAWN
17
DELISTED
Day One Biopharmaceuticals
DAWN
| $93.2M | 1.76% |
7,809,852
+769,230
| +11% | +$10M |
|
18
RxSight
RXST
$254M
| $87.9M | 1.66% |
3,052,796
| – | – |
|
19
Cogent Biosciences
COGT
$6.76B
| $76M | 1.43% |
6,416,147
+416,666
| +7% | +$4.78M |
|
20
PepGen
PEPG
$118M
| $72.7M | 1.37% |
8,131,952
| – | – |
|
|
21
Axsome Therapeutics
AXSM
$11.7B
| $71.9M | 1.36% |
+1,000,000
| New | +$73.8M |
|
|
RNAM
22
DELISTED
Avidity Biosciences
RNAM
| $71.2M | 1.34% |
6,416,998
| – | – |
|
23
Vor Biopharma
VOR
$1.06B
| $70.3M | 1.33% |
1,137,444
| – | – |
|
24
GH Research
GHRS
$1.92B
| $66.3M | 1.25% |
5,587,333
+6,172
| +0.1% | +$63.3K |
|
25
Wave Life Sciences
WVE
$1.12B
| $62.6M | 1.18% |
17,202,009
| – | – |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, RA Capital Management held 63 positions worth $5.3B, up 20% from $4.42B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
RA Capital Management deployed $397M of net new capital in Q2 2023, opening 4 new positions and adding to 10 existing holdings. Its largest new stake was Axsome Therapeutics: 1,000,000 shares worth $71.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.
On the sell side, the largest reduction was Immunogen Inc, an estimated $231M trimmed.
- RA Capital Management's largest Q2 2023 buy was Axsome Therapeutics: 1,000,000 shares worth $71.9M.
- RA Capital Management added most to Ascendis Pharma A/S in Q2 2023, an estimated $371M increase.
- RA Capital Management's biggest Q2 2023 reduction was Immunogen Inc, cutting an estimated $231M.
- RA Capital Management fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $91M.
- RA Capital Management's ten largest holdings make up 58% of its $5.3B portfolio in Q2 2023.
- RA Capital Management opened 4 new positions and closed 9 in Q2 2023.
- RA Capital Management's portfolio value rose 20% quarter-over-quarter to $5.3B.
Based on RA Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.